Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, provides an update on biomarkers for antibody-drug conjugates (ADC) used in urothelial carcinoma, which are necessary to identify patients who will benefit from treatment and reduce toxicity. Whilst the Phase III EV-302 trial (NCT04223856) failed to elucidate novel biomarkers, nectin-4 and circulating tumor DNA (ctDNA) have been subsequently identified as potential biomarkers. Dr Grande additionally highlights radioligands as a promising strategy to find biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть